(PRWEB) February 28, 2012
An article appearing at Forbes online suggests that new microchip technology developed at the Massachusetts Institute of Technology might help patients suffering from osteoporosis get the correct dose of medication without having to endure injections or swallow pills.
Robert Langer and Michael Cima, two MIT researchers working with the company MicroCHIPS, Inc., have developed a microchip implant capable of delivering prescription medications to patients. The chip, in development for about ten years, just completed its first human test, prompting the researchers to claim, “It passed with flying colors.”
The microchip implants were tested on seven women between the ages of 65 and 70 who suffer from osteoporosis. In all seven patients, the chip delivered the correct dose of medication without any adverse side effects. Some bisphosphonate medications are administered by injection, rather than in pill form like Fosamax. The idea behind the microchip implant is to effectively deliver an accurate dosing of medication while ensuring compliance on the part of patients. Many persons cannot, or will not inject themselves with medication.
Cima commented in an MIT press release: “Compliance is very important in a lot of drug regimens, and it can be very difficult to get patients to accept a drug regimen where they have to give themselves injections. This avoids the compliance issue completely and points to a future where you have fully automated drug regimens.”
Langer commented, “This trial demonstrates how drug[s] can be delivered through an implantable device that can be monitored and controlled remotely, providing new opportunities to improve treatment for patients and to realize the potential of telemedicine. The convergence of drug delivery and electronic technologies gives physicians a real-time connection to their patient’s health, and patients are freed from the daily reminder, or burden, of disease by eliminating the need for daily injections.” Right now, the implant is only capable of being monitored within very short distances, but the researchers are currently working on its programming functions.
Despite being the most popular osteoporosis treatment medication on the market, Fosamax has been linked to several serious side effects. In 2004, researchers found a causal connection between Fosamax and osteonecrosis of the jaw, a condition where the jawbone dies due to a lack of blood supply. More recently, people have suffered low-impact femur fractures after falling from standing height or less. Evidence is building that taking Fosamax or similar medications for the treatment of osteoporosis causes a dramatic increase in risk of this particular kind of rare fracture to the thigh bone.
The Rottenstein Law Group urges anyone whose friend or relative has been prescribed Fosamax or another osteoporosis drug to reach out to that person and recommend that he or she consult a physician immediately and then speak to a qualified personal injury lawyer. The Rottenstein Law Group maintains a Fosamax Lawsuit Information Center at http://www.fosamaxfemurfracturelawsuit.com. The site has features that allow for easy sharing, including links for automatic posting on Facebook and Twitter, specifically to enable visitors to spread the word about the dangers of Fosamax.
About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients in consumer product injury, mass tort, and class action lawsuits in a compassionate manner. http://www.rotlaw.com
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
1259 Veeder Drive
Hewlett NY 11557
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)